Analysis of Normal-Tumour Tissue Interaction in Tumours: Prediction
                    of Prostate Cancer Features from the Molecular Profile of Adjacent Normal
                    Cells by Trevino, Victor et al.
Analysis of Normal-Tumour Tissue Interaction in
Tumours: Prediction of Prostate Cancer Features from
the Molecular Profile of Adjacent Normal Cells
Victor Trevino
1,6, Mahlet G. Tadesse
2, Marina Vannucci
3, Fatima Al-Shahrour
4, Philipp Antczak
1, Sarah
Durant
1, Andreas Bikfalvi
8,9, Joaquin Dopazo
4, Moray J. Campbell
5,7, Francesco Falciani
1*
1School of Biosciences and IBR, University of Birmingham, Edgbaston, United Kingdom, 2Department of Epidemiology & Biostatistics, University of Pennsylvania School
of Medicine, Philadelphia, Pennsylvania, United States of America, 3Rice University, Houston, Texas, United States of America, 4Bioinformatics Department, Centro de
Investigacio ´nP r ı ´ncipe Felipe, Valencia, Spain, 5Institute of Biomedical Research, School of Medicine, The Birmingham University, Birmingham, United Kingdom,
6Computer Science Department & Biomedical Engineering Program, Instituto Tecnolo ´gico y de Estudios Superiores de Monterrey, Nuevo Leon, Mexico, 7Department of
Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America, 8INSERM U920, Talence, France, 9University Bordeaux I,
Talence, France
Abstract
Statistical modelling, in combination with genome-wide expression profiling techniques, has demonstrated that the
molecular state of the tumour is sufficient to infer its pathological state. These studies have been extremely important in
diagnostics and have contributed to improving our understanding of tumour biology. However, their importance in in-
depth understanding of cancer patho-physiology may be limited since they do not explicitly take into consideration the
fundamental role of the tissue microenvironment in specifying tumour physiology. Because of the importance of normal
cells in shaping the tissue microenvironment we formulate the hypothesis that molecular components of the profile of
normal epithelial cells adjacent the tumour are predictive of tumour physiology. We addressed this hypothesis by
developing statistical models that link gene expression profiles representing the molecular state of adjacent normal
epithelial cells to tumour features in prostate cancer. Furthermore, network analysis showed that predictive genes are linked
to the activity of important secreted factors, which have the potential to influence tumor biology, such as IL1, IGF1, PDGF
BB, AGT, and TGFb.
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Introduction
The application of functional genomics technologies, particu-
larly gene expression profiling, has provided the scientific
community with the tools to characterize the molecular state of
cells and tissues at a genome level. These technologies coupled
with the ability to dissect specific cell types from a complex tissue
have created an unprecedented opportunity to characterise the
molecular identity of specific cell types in the context of a complex
tissue [1]. Following this approach, gene expression profiling have
been applied to generate the transcriptional profile of tumour cells
that are predictive of both tumour features and clinical outcome in
a variety of human cancers [2]. Many genome-wide studies
however are often analyzed not taking explicitly into consideration
that components of the extra-cellular matrix (ECM) (matrix
proteins, soluble grow factors and chemokines) secreted by normal
cells, adjacent to the tumour site, heavily influence the biology of
the tumour. Recently, stromal cells have emerged as primary
candidates for playing a role into normal-tumour cell interaction
[3]. These cells secrete most of the enzymes involved in ECM
breakdown, for example they produce growth factors that have a
role in controlling tumour cell proliferation, apoptosis, and
migration. They also secrete pro-inflammatory cytokines involved
in chemoattraction and activation of specific leucocytes and
therefore play a role in determining inflammatory responses [4].
Growth factors and cytokines are also involved in the neoplastic
transformation of cells, angiogenesis, tumour clonal expansion and
growth, passage through the ECM, intravasation into blood or
lymphatic vessels and the non-random homing of tumor metastasis
to specific sites. Many of these factors are also secreted by normal
epithelial cells, immune cells and endothelial cells in proximity of
the tumour mass. It has also been shown that the stroma may
impact on the response to anti-tumour therapy. Indeed, the
presence of CD11b+ leucocytes confers resistance to anti-
angiogenesis therapy [5].
Furthermore, pre-treatment of the stroma with anti-angiogen-
esis molecules prior to tumour implantation in mouse tumour
models may paradoxically increase tumour development [6,7].
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e16492This illustrates that the quality of the tumour stroma may
significantly influence tumour development.
The importance of the micro-environment in determining the
onset and progression of cancer arises the question whether it may
be possible to predict the patho-physiology and clinical outcome of
the tumour from specific components of the molecular state of
normal cells. If possible, we would expect these molecular
signatures to represent important components of cell-cell cross-
talk involved in specifying the development of cancer.
We addressed this question by developing statistical models
based on a genome wide profiling of normal tissue adjacent the
tumour and identifying aspects that are predictive of cancer
features.
We have analyzed two different prostate cancer microarray
datasets available in the public domain [8,9]. We show that in
both datasets the molecular state of cells adjacent to the tumour is
predictive of clinically relevant cancer features. These pathways
are informative molecular signatures and represent pathways
involved in the production and response to secreted factors.
These findings support the potential relevance of normal tissue
biopsies in the diagnosis and prognosis of prostate cancer. This
approach also provides a generally applicable analysis strategy to
identify key pathways involved in cell to cell communication.
Results
Statistical modeling establishes a link between the
molecular state of normal cells and tumor histo-
pathological features
The initial objective of our analysis was to test whether the
molecular profile of normal cells is predictive of cancer features.
We initially considered two important aspects of prostate tumour
physiology: the degree of organization of tumour cells defined by a
histo-pathological scoring system called Gleason score, and the
ability of tumour cells to penetrate the organ capsule summarized
by a binary histo-pathological score called capsular penetration.
The level of differentiation of tumour cells measures the tendency
of cells to aggregate in glandular-like structures that are
reminiscent of the organization of the normal tissue. The Gleason
score can be used to define two main classes. The first is
characterized by low-grade tumours that display a highly
organised structure (correspondent to a score below or equal to
6) whereas a second class is characterized by high-grade tumours
cells that are dispersed in the matrix and do not show a tendency
to form glandular-like structures (correspondent to a score above
or equal to 7). By contrast capsular penetration describe the extent
to which cells have evaded the capsule that surrounds the prostate.
Our analysis aimed to link the molecular profile of normal cells
to differentiation level (low versus high differentiation) and
capsular penetration (positive versus negative). This was achieved
through the development of statistical models that were based on
the molecular profile of normal cells and predictive of the sample
classes, specifically Gleason score and capsular penetration.
For this purpose we applied two different multivariate modelling
approaches (GA-MLHD and BVS methods) to two independent
datasets developed by Singh et al. [9] and by Lapointe et al. [8].
The two statistical modelling approaches are designed to search
for multi-gene markers that maximise the distinction between
sample classes. Using these methods, we have developed represen-
tative models that were predictive of tumour features by means of
the gene expression profile of normal cells. Classification accuracy
and size of these models were comparable to the ones developed
using the molecular state of tumour cells (Table 1). Representa-
tive models developed with the BVS and GA-MLHD methods
represent optimal predictive subsets that are based on a very
similar number of genes and have a high degree of overlap at the
gene level, suggesting that our results are independent of the
methodology used (Figure 1 and Figures S1, S2, and S3).
Consistent with the relatively small degree of overlap between the
microarray platforms (,=8%, see the Data Processing section in
the Text S1 for details), the representative models developed from
the two independent datasets have no genes in common.
Further analysis of the relative contribution of the individual
genes to the sample separation was performed using a principal
component analysis (Figure 2). This approach has revealed that
genes involved in cell communication pathways are predictive of
capsular penetration. Within the gene set selected by the GA in the
normal tissue dataset, a combination of higher expression of the
gene PRELP and a lower expression of the genes UBE4A, ZNF146
in the normal cells was predictive of tumour capsular penetration.
In the gene set developed by applying the BVS procedure on the
normal tissue dataset, a high expression of PPP2R4, PRELP,
CALLA, ISG20L2 was predictive of tumour capsular penetration.
The models developed from the Lapointe dataset revealed that
lower expression of OAT and higher expression of PCGF5 and
MYCN in the GA model and lower expression of IGF1 and PRAC
and higher expression of PCGF5 and CPSF7 are predictive of
capsular penetration.
The link between normal and tumour shown in this analysis is
also supported by a univariate analysis which we have performed
using a broad spectrum of available methodologies (Figure S4).
Specificity of gene signatures predictive of cancer histo-
pathological features
Adjacent normal and tumour tissues are morphologically
distinct. However, they show a degree of molecularly similarity
which is in part a consequence of sharing the same micro-
environment [10]. We therefore wondered whether the predictive
models we have developed from normal epithelial cells represent a
molecular signature that is specific to normal tissue or whether the
expression of the predictive genes in tumour cells may also be
predictive of tumour features. In order to address this hypothesis,
we took genes selected by our modelling strategies developed from
the normal tissue datasets and tested whether their expression in
the tumour issue was predictive of cancer features.
We also challenged the prediction accuracy of models deve-
loped from the tumour data by performing the corresponding
comparison in the normal dataset. In both cases, the prediction
accuracy of the models is close to 50% (which correspond to the
expected accuracy of a random guess) (Figure 3). This analysis
therefore shows that the molecular signatures we have identified
are specific for the tissues (normal or tumour) they have been
selected to represent.
Functional networks linked to predictive signatures
representing normal epithelial cells expression profiles
include important cytokine and growth factor signals
In order to facilitate the biological interpretation of the genes
represented in our statistical models we used the IPA analysis
software to perform an in depth analysis at the network level. To
ensure our analysis covered the full spectrum of possible solutions,
we used as input to the IPA software the list of genes represented
in the collection of predictive models identified from the normal
tissue by the GA procedure. These covers a wider spectrum of the
solution space respect to the representative models described
above (Figure 1 and 2) and represent 239 and 259 genes for
Singh and Lapointe datasets respectively. In this analysis we
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prognostic relevance. The network analysis was performed
independently in the two datasets and the most significant
networks (statistically significant and with .50% target genes
represented in the network) were selected for further analysis.
In both datasets, predictive genes were part of networks linking
extracellular molecules such as the pro-inflammatory cytokine
IL1b, the pro-metastatic chemokines CX3CL1 and CCL20 and
the growth factors IGF1, TGFb and PDGF BB with the activity
of the nuclear transcription factors NFKb, HF4A, TP53,a n d
MYC.
Figure 4 describes the most significant networks identified by
the IPA application representative of the models based on the
molecular state of normal cells and predictive of capsular
penetration in the Lapointe et al. dataset (see Table S2 for the
full list of significant networks identified by IPA). Figure 4A shows
a network represented by the interaction between the pro-
inflammatory cytokine IL1b and the transcription factor NFkB.
Figure 4B–D represent three interconnected sub-networks which
involve the interaction between several growth factors genes and
the transcription factors P53 (TP53) and C-MYC (MYC). More
specifically, Figure 4C represent a network including the growth
factors IGF1, its receptor IGF1R and PDGF BB. Figure 4B
represents the interaction between the extracellular factors
Angiotensin (AGT), the growth factor TGFb and the Notch
receptor ligand Jagged (JAG). Figure 4D on the other hand
represents genes that are either directly or indirectly connected to
the transcription factor c-myc (MYC).
The top four most significant networks identified from the
Singh dataset (Figure S5) represent genes connected to the
same cytokines and growth factors identified in the Lapointe
dataset. This interesting observation suggests that, despite the
limited amount of overlap at the gene level, models derived from
the two dataset may represent functionally similar molecular
networks.
Expression of predictive cytokines, growth factors and
their receptors in Prostate Cancer progression
In order to improve understanding of the biological significance
of the IPA networks we analysed the expression of genes in
different stages of prostate cancer progression. We focused the
investigation on a small subset of 20 genes representing the
secreted factors included in the IPA networks and their receptors
(Table S3).
With the purpose of limiting the interference of stromal cell
contaminants, we selected a dataset representing a microarray
analysis of seven types of normal and tumour epithelial cells
populations, purified by laser-capture micro-dissection (LCM)
reported by Tomlins et al. [11]. These included, normal prostate
cells purified from healthy prostates (Nor), normal cells from
benign prostate hyperplasia (BPH), normal cells adjacent the
tumour (adj), tumour cells from prostatic intraepithelial neoplasia
(PIN), tumour cells from low grade prostate carcinoma (L-PCA),
tumour cells from high grade prostate carcinoma (H-PCA) and
tumour cells from prostate cancer metastases (Meta).
We hypothesize that since the 20 genes we selected were
included in models highly predictive of tumour capsular
penetration, they may also be differentially expressed during
prostate cancer progression. We tested this hypothesis by
comparing the seven LCM cell populations. We discovered that
a surprising large proportion of these genes were differentially
expressed (75% at p,0.001 and 95% at p,0.05)( Table S3,
Figure 5, S7 and S8). Further support to the relevance of the
gene expression signature we had identified came from the
observation that the two dimensional cluster analyses performed
using the matrix of differential gene expression profiles (average
expression for each group), recapitulated the expected relationship
between the different stages in the development of prostate cancer
(Figure 5A). More precisely, normal cell populations clustered
together followed by PIN and a cluster of L- PCA and H-PCA.
The Metastatic cell group clustered aside.
Table 1. Accuracy, size, and gene content of representative models developed from normal and tumour data.
Class+Tissue
Dataset GA-MLHD Acc BVS Acc
CP+N
Singh et al.
WDR18, ZNF146, MBD3, UBE4A, PRELP*, MXRA7*,
MME/CALLA*
86.1 (7) RPS2, CCL13, VCP, PRELP*, PPP2R4, ISG20L2,
MXRA7*, ARAF, MME/CALLA*
78.0
(9)
CP+T
Singh et al.
LUZP1, SORL1, TMSL8*, HYOU1, ST14, TALDO1*,
DGCR6L
97.4 (7) TMSL8*, RPL35, HIST1H2BK, KRT8, RAB1A, TSPAN1,
TALDO1*, PDLIM5, GADD45G, GDF15
92.0
(10)
GS+N
Singh et al.
BZRPL1, TEGT*, IDH3B, MID1, D83779, PTGDS*,
PFDN5, PTGDS*
89.7 (8) HBA1/2, PABPC1/3, TEGT*, PRSS22, DNAJC4,
PTGDS*, PNPLA2, USP9X, PTGDS*
92.5
(9)
GS+T
Singh et al.
TMSB4X/L3, SLC6A7, AA524802, ABCC10, INHBB,
SULT2B1, PHYHIP, SLC1A5, ACPP*,C 7 ,ACPP*,
NR4A1*
91.6 (12) VIM, R42599, ARF1, RBM3, EIF4G2, ACPP*, VEGF,
SPARCL1, COL4A2, HLA-DPB1, DSTN, UBB, ACPP*,
NR4A1*
90.0
(14)
CP+N
Lapointe et al.
H27617*, PCGF5*, IGF1*, OAT, EPHB3, BEX1,
C12orf56, H08136*, IDH3G, CYR61, TNRC6B*,
CX3CL1*, MYCN
89.2 (13) H27617*, FLJ12529, PCGF5*, PRAC, IGF1*,
H08136*, TNRC6B*, CX3CL1*
97.4
(8)
CP+T
Lapointe et al.
MT1X*, R20199*, NEBL, ACSL3, CXCL14*,
AI018472
96.5 (6) AA420602, H19, MT1X*, CIP29, R20199*, PLGLB2,
ZNF533, CXCL14*, NAT1
100.0
(9)
GS+N
Lapointe et al.
FOLR1, APOD, NALP2*, CLSPN, N39101, ISL1*,
KITLG, N46872, APOD, KBTBD10*, ZNF185*,
AA699363, FUT8, KLK2*
93.8 (14) NALP2*, ISL1*, KIAA1244, KBTBD10*, ZNF185*,
AI018026, KLK2*, RERG
97.1
(8)
GS+T
Lapointe et al.
MOCOS, ITGBL1*, PLEKHH2, WDR72*, DUSP8*,
RBM12B, MCOLN3
94.4 (7) ITGBL1*, S100A1, KBTBD10, AA699944, WDR72*,
MTMR9, DUSP8*, PUNC
97.1
(8)
Accuracy (Acc) are expressed in percentage and model size are shown in brackets. Marked genes in bold and asterisk appear in both methods (GA-MLHD and BVS).
Dataset is indicated. CP+N – Capsular Penetration class from Normal data, CP+T – Capsular Penetration Tumour, GS+N – Gleason Score Normal, GS+T – Gleason Score
Tumour.
doi:10.1371/journal.pone.0016492.t001
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predictive power of normal cells signature is the observation that
normal cells adjacent the tumour showed significant differences in
respect to Normal cells and BPH (Figure 5B). Five genes (IL1R,
LOX and TGFBR, CX3CL1 and CYR61) were differentially expressed
between the three populations of normal cells. More specifically,
normal cells adjacent to the tumour (Norm) were characterized by a
lower expression of the tumour suppressor gene LOX, the receptors
for interleukin 1 (IL1R)a n dTGFb (TGFBR) and by a higher
expression of the pro-tumour genes CYR61 and CX3CL1.
We then examined the expression of individual genes across the
different stages of tumour progression in relation to the networks
identified by the IPA software (Figure 4).
The cytokine IL1b, identified by the IPA analysis as linked to
the activation of the pro-metastatic chemokines CX3CL1 and
CCL20 (Figure 4A), was up-regulated in the tumour cell
populations PIN and H-PCA (Figure 5A, and 5C), whereas
the expression of IL1R1, which mediated the activity of IL1b,
follows an opposite trend (Figure 5A, B and C). The pro-
metastatic chemokine CX3CL1 was expressed at higher levels in
adjacent cell population respect to PIN, L-PCA and H-PCA but
not in Meta cells (Figure 5E). The expression of the LOX gene
was found higher in all tumour cell populations relative to adjacent
and normal cells (Figure 5F) consistent with the fact that higher
expression of LOX has been associated to hypoxia-induced
metastasis in breast, head, neck cancers [12,13].
The expression of AGT, TGFB and JAG1 were linked in a
different IPA network (Figure 4B). The expression of Angioten-
sinogen (AGT) is higher in adjacent cells compared to PIN, L-PCA
and H-PCA whereas JAG1 follows an opposite trend (down
regulated in adjacent cells respect to L-PCA, H-PCA and Meta). If
angiotensinogen is produced at higher levels in adjacent cells one
of the activating enzymes which convert the product of the AGT
gene in angiotensin II (ACE) is instead higher in PIN and L-PCA,
suggesting the potential for utilization in tumour cells at lower
stages of prostate cancer development. The finding that AGT and
JAG1 have opposite trends supports the hypothesis that AGT may
repress the expression of JAG1 (Figure S8 panels E and F). This
connection was reported by the IPA software (Figure 4B) but was
supported by an endothelial cell culture experimental model [14].
These results are consistent with the hypothesis that this
mechanism may also be relevant in prostate cancer.
Figure 1. Multivariate Models for Capsular Penetration using Normal data. The figure shows the heat maps representing the expression
profile of genes selected by the GA and BVS models in both Lapointe and Singh datasets from the normal tissue data. Each quadrant in the figure
represents a combination of a modelling approach and a specific dataset. Genes present in GA-MLHD and BVS for the same dataset are highlighted in
red. Accuracy is reported below each heatmap. GeneBank accession number and gene symbol are shown on the left side of the heatmap. Brighter
green or red colours in heatmaps represent lower or higher relative expression respectively. t-test p-value is shown for comparison with the
differential expression criteria commonly used in univariate variable selection approaches.
doi:10.1371/journal.pone.0016492.g001
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tumour-promotingfactorsIGF1,PDGFBBandCYR61(Figure4C).
Although the expression of PDGF is constant in all cell populations,
its receptor (PDGFR) is higher in H-PCA and Meta cell populations
compared to adjacent cells. The expression of CYR61 is higher in
adjacentcellsrespect toPINandMeta cell populations(FigureS8).
Discussion
We have demonstrated that normal epithelial cell signatures are
predictive of important features of prostate cancer. This finding has
potential clinical implications as it may suggests that the molecular
state of normal cells has prognostic value. At the molecular level,
network analysis has revealed that our approach has the potential to
identify genes involved in the disease pathogenesis. These include key
genes encoding cytokines and growth factors expressed by normal
epithelial cells and known to influence the biology of the tumour.
Cytokine induced production of pro-metastatic
chemokines
The network shown in Figure 4A and Figure S5 represents
signalling of the pro-inflammatory cytokine interleukin 1 (IL1b)
through the activation of the NFkB complex. The IPA software
linked IL1b to the expression of the known pro-metastatic
chemokines CX3CL1 [15] and CCL20 [16] in an endothelial cell
culture model [14].
Although induction of these chemokines by IL1b has not been
demonstrated to date, several pieces of evidence support the
relevance of this mechanism in prostate cancer progression.
Voronov et al. [17] have shown that IL1b is required for tumour
invasiveness and angiogenesis in a mouse breast cancer model and
provided evidence for the same mechanism in prostate cancer.
More recently, an Interleukin-1 receptor antagonist haplotype
have been found to be associated with prostate cancer risk [18]
suggesting that the results of the animal model may be relevant in
a clinical setting.
The analysis of the LCM dataset showed that IL1b is expressed
at higher levels in PIN and H-PCA than in adjacent cell
populations whereas the latter expressed higher levels of the
receptor (ILR1)( Figure 5).
Furthermore, normal epithelial cells express higher levels of
CX3CL1 respect to their tumour counterpart while its receptor
(CX3CR1) is expressed in tumour cells [19]. This chemokine
promotes migration of cancer cells and metastases formation in a
Figure 2. PrincipalcomponentrepresentationforCapsularPenetrationusingNormalData. Thefigure showstheresultofa PCArepresenting
sampleseparationon thebasis of the expression in normal tissueof genes selectedby themodelling procedures.Each quadrant in thefigure represents
a combination of a modelling approach and a specific dataset. Each quadrant contains a 2D plot representing the separation of capsular penetration
negative (black close circles)andpositive(red closecircles)samples (plots B,D, F andH)andabarchart (plotsA,C,E andG)representingthe PCloadings
(x axis) for each gene component (y axis). Note that PC loadings represent the contribution of every gene to class separation. Dashed lines delimitated
genes with larger contribution that are discussed in the manuscript. Genes present in GA-MLHD and BVS for the same dataset are highlighted in red.
doi:10.1371/journal.pone.0016492.g002
Normal-Tumour Cell Interaction in Prostate Cancer
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e16492number of cancers [20] including prostate [21]. The production of
this chemokine by epithelial cells adjacent the tumour has
therefore the potential to induce tumour cell migration. Similarly,
prostate normal epithelial cells produce the chemokine CCL20 and
the expression of its receptor (CCR6) in prostate cancer cells has
been recently found to be a predictor of tumour aggressiveness
[22].
The network also includes LOX, which is represented as an
indirect repressor of the NFKb complex [23] [24]. The biological
role of LOX in cancer is complex. LOX has been reported to have
tumour suppressor activity [25] and can inhibit proliferation of the
prostate cancer cell line DU 145 via a mechanism involving
interference with FGF2 binding and signalling cascade [23].
However, LOX has also been reported to have an important
tumour promoting activity by favouring metastasis in breast, head,
and neck cancers [12] [13]. The analysis of the LCM dataset has
shown that the expression of the LOX is higher in all tumour cell
populations (PIN, L-PCA, H-PCA and Meta) respect to adjacent
cells. This may be consistent with the tumour-promoting role of
LOX but it raises the question whether the amount of LOX
produced by epithelial cells would be able to significantly affect
tumour cells.
Figure 3. Accuracy and Tissue specificity of representative models. The predictive accuracy of the models developed using normal tissue
(panel A, filled circles) is comparable to those models developed using tumour tissue (panel B, filled diamonds). When models developed using
normal tissue are trained and tested using data from tumour tissue, the prediction power is decreased considerably (empty circles). Likewise, tumour
models trained and tested with data from normal tissue are also non predictive (empty diamonds).
doi:10.1371/journal.pone.0016492.g003
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metastatic signals in normal epithelial cells is an interesting one.
We have initially tested this hypothesis by treating the normal
prostate cell line RWPE1 with recombinant IL1b and discovered
that both CCL20 and CX3CL1 are significantly up regulated 6
and 24 hours after stimulation. LOX is instead only transiently up-
regulated six hours after IL1b stimulation (Figure S6). This
observation suggests that our hypothesis may be correct.
Role of IGF1 and PDGF BB in Prostate Cancer
development
The IPA software identified a network representing interactions
with the growth factors PDGF BB and IGF1 (Figure4CandS5B-C).
The role of IGF1R in malignant transformation is well
documented [26]. IGF1R is over-expressed by many tumour cell
lines and targeted disruption of the IGF1R gene can abolish cell
transformation.
PDGF BB has a dual role on prostate cancer development. It
directly promotes tumour cell proliferation and invasion [27].
Platelet-derived growth factor induces proliferation of hyperplastic
human prostatic stromal cells [27].
In addition, PDGF BB has been described as a potent inductor
of angiogenesis and promotes pericyte recruitment [28]. Its activity
is synergistic to IGF1 in promoting migration of human arterial
smooth muscle cells [29].
The IPA network shows that PDGF BB and IGF1 can
transcriptionally activate CYR61 [30] [31]. CYR61 is an extracel-
lular matrix-associated protein that promotes adhesion, migration,
proliferation, and angiogenesis. CYR61 is required for breast
tumorigenesis and cancer progression [32] [33] and promote
prostatic cell adhesion and proliferation [34] [35]. CYR61 also
promotes invasion when tumor stroma is irradiated before tumor
implantation in a model of skin cancer [36]. Relative to LCM
normal (norm) cells, CYR61 is up regulated in LCM BPH, normal
Figure 4. Functional networks representing known interaction between genes expressed in normal tissue and selected in the
models predictive of capsular penetration. The figure represents the four most significant networks selected by the IPA software. Genes
represented by blue shapes are present in the collection of models collected by the GA-MLHD procedure. Genes represented with red shapes
represent genes in the collection of models but also included in the representative most predictive models. Genes in the networks are arranged by
cellular localization (extracellular, membrane, cytoplasm and nucleus). Note that the IPA software search for statistically significant sub-networks of a
given maximum size to simplify their visualization. Nevertheless, in this case these are linked as indicated by red dashed arrows connecting specific
network components.
doi:10.1371/journal.pone.0016492.g004
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e16492cells adjacent to the tumor and both low and high-grade prostate
carcinoma (Figure 5B and S8). The receptor of PDGF BB,
PDGFBR, has a similar trend, which is consistent with its potential
activator role.
Although protein measurements may be necessary to support
this analysis, it is not unreasonable to hypothesize that adjacent
normal epithelial cells may produce sufficient CYR61 to influence
tumor cells.
The expression of targets of TGFb in the normal tissue
predict tumour capsular penetration
The networks represented in Figure S5D and 4B represent the
connection between genes including models predictive of tumour
capsular penetrations and TGF.
TGFb has a complex role in tumour development. It can either
promote or inhibit tumour development in a context dependent
manner [37]. In normal epithelia and early stages of tumour
development, TGFb has role in regulating tissue homeostasis and
is considered an anti-tumour factor preventing incipient tumours
from progressing towards malignancy [5]. Furthermore, TGFbin-
hibits recruitment of pericytes to the vasculature, thus decreasing
vessel maturation and flow which may also negatively impact on
tumour development [38].
At later stages of tumour development, TGFb has been shown
to promote tumour development and metastases formation. Of
particular relevance, TGFb1 reverses inhibition of COX-2 with
NS398 and increases invasion in prostate cancer cells [39]. The
development of a pro-tumour activity of TGFb in tumour
progression is often associated to mutations, which eliminate the
tumour suppressor activities of TGFb and promote growth and
invasion. Another pro-tumour effect of TGFb is linked to induce
immune system tumour tolerance [37]. Consistent with these
findings, recent reports suggest that in prostate cancer TGFb may
be relevant therapeutic target [40] [39].
We found that in the LCM cell populations TGFb is expressed
at high levels in normal cells adjacent the tumour (Figure 5 and
S7). The predictive power of TGFb response signatures in normal
epithelial cells may therefore be the reflection of the amount of
active TGFB present in the microenvironment that, at least in part
may be produced by normal epithelial cells adjacent to the
tumour.
Angiotensinogen and Notch in Prostate Cancer
The network shown in Figure 4B involve the interaction
between the Angiotensin precursor Angiotensinogen (AGT) and
the Notch ligand JAG1. A functional Renin-Angiotensin system
has been demonstrated in prostate cancer [41] [42]. In addition its
canonical role in regulating blood pressure it is now recognized
that Angiotensin can influence several growth factor pathways
[41], including oncogene activation [43]. It has been recently
shown to be a clinically relevant factor in the progression of
prostate cancer and a potential avenue for treatment [41] [44]
[45]. AGT is up regulated in normal epithelial cells adjacent the
tumour compared to PIN and PCA (Figure S8E). This
Figure 5. Analysis of LCM cell populations representative of prostate cancer progression. The figure represents the results of the analysis
performed on the dataset developed by Tomlins et al. [11]. Different cell populations are labelled as follows. Normal cells (norm), normal cells
adjacent the tumour (adj), benign prostate hyperplasia (MPH), low grade prostate carcinoma (L-PCA), high-grade prostate carcinoma (H-PCA) and
metastatic cells (meta). Panel A shows a two-dimensional cluster analysis performed on the genes differentially expressed (p,0.01) across the seven
LCM purified normal and tumour epithelial cell populations. Panel B represents the expression level (y axis) of genes differentially expressed
between norm, adjacent and BPH (represented on the y axis). Levels of individual genes across all stages are presented in panels C-F and in Figure
S8.
doi:10.1371/journal.pone.0016492.g005
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by normal epithelial cells.
The IPA network (Figure 4B) links AGT to the transcription of
JAG, another factor known to have context-dependent effects on
tumour development. In vascular cells, inhibition of Jagged
promotes angiogenesis [46] favouring tumour growth. On the
other hand Jagged 1 favours proliferation and expansion of
prostate tumours [47].
In LMC cell populations tumour cells express higher levels of
JAG1 than adjacent normal epithelial cells (Figure 5 and S7).
Hence, the effective contribution of normal cell expressed JAG1
on tumour development is unclear.
Conclusions
Ultimately, our approach provides a way to identify molecular
networks whose activity in normal epithelial cells is predictive of
tumour features. Prostate cancer progression rates among so-called
‘‘favourable prognosis’’ localized tumours (e.g. Gleason score ,6)
are not precisely predicted by grade and stage at diagnosis. This
lack of diagnostic accuracy has contributed to the conundrum of
CaP over-screening and possibly over-treatment [48,49]. A similar
lack of prognostic accuracy is apparent when tumours recur
during androgen depravation therapy. Greater diagnostic accura-
cy is thus imperative to distinguish at early stages indolent disease
from aggressive phenotypes that can progress rapidly, and at late
stage disease the lethal phenotypes.
Lessons from breast cancer studies have taught us that
significant strides in diagnosis (and thus treatment) can be made
by applying multiple genetic parameters to define disease with
greater clinical resolution (reviewed in [50]). Such approaches
have progressed less quickly in prostate cancer [51]. The current
study suggests this need and gap in understanding can be met by
utilizing gene expression signatures in the normal prostate tissue
adjacent to the tumour as novel functional molecular biomarkers.
In early stage disease especially identification and sampling of the
tumour within the prostate gland can be highly challenging.
Therefore it is highly advantageous and attractive to utilize gene
expression signatures in the readily sampled normal tissue to make
robust prognostic inferences concerning the tumour.
An important question is whether the statistical relationships we
have discovered with our analysis reflect a key aspect of tumour
microenvironment in which normal epithelial cells influence
tumour biology. Although it is hard to provide a conclusive
answer, the information available in the literature and our
experimental validation in a normal epithelia prostate cell line
(Figure S6) indicates that this may be a plausible hypothesis.
Despite the limited overlap at the gene level, mainly caused by
our stringent pre-processing criteria (see methods section for
details), the analyses we have performed on the two independent
datasets provided similar results at the network level. This finding
reinforces the validity of the overall analysis strategy. From a
methodological standpoint our approach therefore has potential
for formulating hypothesis on genes playing a role in controlling
the development of cancer. The approach is general and likely to
be applicable to other datasets for which tumour and adjacent
normal samples are available.
Materials and Methods
Datasets
Our analysis is based on two independent large prostate cancer
studies performed using different array technologies. In both
studies, cells from tumour and adjacent normal tissues have been
isolated and the extracted RNA has been hybridized on human
microarrays for expression profiling. The first dataset used in our
analysis is derived from a study performed by Singh et al. [9] where
52 samples of prostate tumours and adjacent normal tissues were
collected from patients undergoing radial prostatectomy; then
profiled using Affymetrix Genechip technology. The second
dataset used was collected by Lapointe et al. [52] using cDNA
arrays. In this study 41 paired normal and tumor specimens were
removed from radical prostatectomy. Information about the histo-
pathology of the tumor specimens (Gleason score and Tumor
stage) was available for both datasets. Details of the data
processing for both datasets are available in the supplementary
material. After processing, the two datasets show relatively limited
overlap at the gene level (up to 8%, Table S1). Consequently, we
have opted for the two datasets to be analyzed separately.
Statistical Modeling
Classification methods with univariate variable
selection. Our analysis aims to identify molecular signatures
predictive of two binary variables representing relevant features of
tumor biology. These are the degree of differentiation of the tumor
and the ability of the tumor to penetrate the organ capsule. To
develop such signatures we have initially tested a univariate
variable selection strategy based on an F test in combination with
several classification methods (SVM, DLDA, PAMR, KNN,
SOM) as implemented in the software application Prophet
available in the Web based microarray analysis suite GEPAS
[53]. This application uses a step-wise variable inclusion strategy
to construct increasingly large models from a list of genes ranked
by the value of the F statistics and implement a cross-validation
strategy for error estimation. Results of this analysis are shown in
Figure S4.
Classification methods with multivariate variable
selection. In order to consider the effect of combinations of
genes in the prediction of the histo-pathological variables we have
used a statistical modeling approach in combination with mul-
tivariate variable selection procedures. In order to demon-
strate that our results are independent of a particular method-
ology we developed and compared multivariate classification
models obtained using two independent procedures. These
methods differ for both the variable selection strategy and for
the classification algorithms used. The first approach is a
modification of the Genetic Algorithm –maximum likelihood
discriminant analysis (GA-MLHD) method originally developed
by Ooi and Tan [54]. This method uses a genetic algorithm
approach for variable selection coupled to a MLHD functions
classifier. The GA-MLHD methodology uses an initial random
population of models (called chromosomes) and evolves from them
highly accurate classifiers using a process that mimics natural
selection. Accuracy was estimated as the proportion of guesses in
test samples in a cross-validated manner. In our implementation
[55] we have improved the error estimation strategy by using two-
levels of cross-validations. The first level is used in the evolutionary
step of the GA to evaluate the error in a subset of the dataset using
a k-fold-cross-validation procedure (k=5). The second level is used
at the end of the evolutionary process, when all chromosomes are
selected, to estimate the classification error as an average of the test
error in 40 random splits (2/3 for training and 1/3 for testing)
using the entire dataset. Model sizes of 5 were used, which showed
a higher accuracy than 10 and 20 in average for 10,000 models. In
addition, we have compared the results with models obtained
using a Bayesian variable selection (BVS) approach that we have
developed [56]. This method uses a multinomial probit model as
classifier and Markov Chain Monte Carlo (MCMC) methods to
search multivariate space for informative subsets of the variables.
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[56]. Two runs were made for model sizes 10 and 20. The model
with higher average accuracy was then chosen.
Selecting representative models. Both GA-MLHD and
BVS modeling approaches provide a number of alternative models
with comparable predictive value. These models tend to have a
degree of overlap in their gene composition. It is therefore
meaningful to select a single summary model that represents the
most frequent solutions. In order to do so, for the GA-MLHD
approach, we have used a forward selection procedure applied to
the top 1% most predictive models selected using the GA
procedure. In the case of BVS, we have tested models developed
with the genes that were included in the subsets of variables most
frequently visited by the MCMC search. The final list of models
was generated by the union of the two chains with minimum
average miss-classification error [56]. Interestingly, we have
discovered that representative models developed with the GA-
MLHD procedure largely overlaps with the pooled models from
the BVS approach. We tested the overlap between models selected
by the GA-MLHD procedure in the two datasets at different
processing thresholds. The overlap between the top 50 raking
genes (by frequency of inclusion in the model populations) in
the model populations was always significant (see Tables S4 and
S5).
Tissue specificity of representative models
An important component of our strategy is to demonstrate that
molecular signatures are tissue specific hence they are not
representing a mere reflection of the overall similarity between
normal and tumour tissues. The strategy to demonstrate the
specificity of the gene signatures obtained with the multivariate
variable selection strategy implemented in the GA-MLHD
procedure is described below in two steps.
Step 1: development of representative models. Expression
data from the normal tissue samples are split between training and
test sets (respectively 2/3 and 1/3 of the original dataset). The
training set is used to develop a classification model to predict
cancer features with a cross-validation strategy. Once the represen-
tative models have been developed their classification accuracy is
estimated on the test set.
Step 2: Specificity test. Expression data from the tumour
tissues samples are split between training and test sets (respectively
2/3 and 1/3 of the original dataset). The expression profile of
genes selected in Step 1 (in the samples selected in the training set)
is used to train a classification model to predict Cancer features.
The classification accuracy of the trained model is then estimated
on the test set. The classification accuracy estimated in step 2 is
then compared to the classification accuracy estimated in step 1 to
establish the tissue specificity of the gene signatures (Figure 3). In
order to demonstrate the tissue specificity of models based on the
molecular profile of tumour tissues we have also performed the
reverse test.
The assessment of the tissue specificity of the molecular
signatures obtained with the BVS procedure has been performed
using a cross-validation procedure for the error estimation as
described in [56].
Analyzing the specific contribution of genes in the
predictive models
Our approach, which is based on multivariate predictive models
selects combination of genes to perform predict tumour features.
Therefore, differential expression between sample classes may not
be always indicative of the relative contribution of a gene to
sample separation. Therefore, in order to graphically represent
sample classification and to estimate the contribution of each gene
for class distinction, we used principal component analysis (PCA).
PCA reduce the original variable space in a handful of principal
components (PC). A PC is defined as a weighted sum of variables
(genes). The weight or loading given to a variable is interpreted as
its importance. For discussion, we focused in genes having absolute
loadings values larger than 0.3 (Figure 2, S1, S2 and S3). In all
cases, the chosen PC (first two) show evident class separation
providing further support for the association of the selected genes
and the sample classes.
Interaction networks and functional analysis of
multivariate signatures: The Ingenuity Pathway Analysis
(IPA) software
The gene sets represented in the populations of models selected
using the GA-MLHD procedure have been analyzed using the
Ingenuity Pathway Analysis (IPA) application (Palo Alto, http://
www.ingenuity.com), a web based application that enables
discovery, visualization, and exploration of biologically interaction
networks.
Gene lists represented in the model populations developed
with normal or tumor expression data to predict capsular
penetration or Gleason score were uploaded into in the
application. Each gene identifier was mapped to its correspond-
ing gene object in the Ingenuity Pathways Knowledge Base.
These genes, called focus genes, were overlaid onto a global
molecular network developed from information contained in the
Ingenuity Pathways Knowledge Base. Networks of these focus
genes were then algorithmically generated based on their
connectivity according to the following procedure implemented
in the IPA software application. The specificity of connection for
each focus gene was calculated by the percentage of its
connection to other focus genes. The initiation and the growth
of pathways proceed from the gene with the highest specificity of
connections. Each network had a maximum of 35 genes for
easier interpretation and visual inspection. Pathways of highly
interconnected genes were identified by statistical likelihood
using the following equation:
Score~{log10 1{
X f{1
i~0
C(G,i)C(N{G,s{i)
C(N,s)
 !
Where N is the number of genes in the genomic network, of
which G are focus genes, for a pathway of s genes, f of which are
focus genes. C(n,k) is the binomial coefficient. Pathways whose Score
were greater than 5 (p,0.0001) were selected for biological
interpretation.
Canonical pathway analysis was performed using the IPA tools
and significance for the enrichment of the genes with a particular
Canonical Pathway was determined by right-tailed Fisher’s exact
test with a=0.01 and a whole database as a reference set.
Analysis of LCM cell populations
The dataset developed by Tomlins et al. [11] was downloaded
from the GEO database and raw data normalized using print tip
normalization. The expression profiles of a subset of 20 genes
(representative of secreted factors and their receptors from the IPA
networks) across samples representing normal and tumour
epithelial cells were then selected to create a secondary dataset.
Differentially expressed genes were then identified by one factor
ANOVA using the software application TMEV [57].
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Figure S1 Multivariate Models for Capsular Penetra-
tion using Tumour data. Genes present in GA-MLHD and
BVS for the same dataset are highlighted in red. Accuracy is
estimated as described in the Material and Methods section.
GeneBank accession number and gene symbol is shown. Brighter
green or red colours in heatmaps represent lower or higher relative
expression respectively. t-test p-value is shown for comparison with
the differential expression criteria commonly used in univariate
variable selection approaches. PCA plots and loadings are used to
show the putative contribution of every gene to class separation.
For example, TALDO1 gene in top heatmap seems to contribute
strongly to positive Capsular Penetration whereas ST14 contribute
weakly to negative Capsular Penetration. PCs were selected by
visual inspection.
(EPS)
Figure S2 Multivariate Models for Gleason Score using
Normal data. Genes present in GA-MLHD and BVS for the
same dataset are highlighted in red. Accuracy is estimated as
described in the Material and Methods section. GeneBank
accession number and gene symbol is shown. Brighter green or
red colours in heatmaps represent lower or higher relative
expression respectively. t-test p-value is shown for comparison
with the differential expression criteria commonly used in
univariate variable selection approaches. PCA plots and loadings
are used to show the putative contribution of every gene to class
separation. For example, TEGT gene in top heatmap seems to
contribute strongly to high Gleason grades whereas D89667
contribute to low Gleason Grades. PCs were selected by visual
inspection.
(EPS)
Figure S3 Multivariate Models for Gleason Score using
Tumour data. Genes present in GA-MLHD and BVS for the
same dataset are highlighted in red. Accuracy is estimated as
described in the Material and Methods section. GeneBank
accession number and gene symbol is shown. Brighter green or
red colours in heatmaps represent lower or higher relative
expression respectively. t-test p-value is shown for comparison
with the differential expression criteria commonly used in
univariate variable selection approaches. PCA plots and loadings
are used to show the putative contribution of every gene to class
separation. For example, ACPP gene in top heatmap seems to
contribute strongly to low Gleason grades whereas TM8B4X
contribute to low Gleason Grades. PCs were selected by visual
inspection.
(EPS)
Figure S4 Univariate gene selection models. Models were
generated using a forward selection procedure that includes,
progressively, genes ranked by a univariate statistic (F-ratio,
horizontal axis). The accuracy is assessed by leave-one-out-cross-
validation for a number of classification methods (vertical axis, see
legends, and the Prophet tool within www.gepas.org [3]).
Maximum accuracy is marked by a dotted horizontal line.
Overall, this univariate gene selection generates comparable
predictive models irrespective of the classification method. More
accurate multivariate models generated by GA-MLHD and BVS
used in this chapter are shown for comparison in red and black
dots. Legends: DLDA - Diagonal Linear Discriminant Analysis,
KNN - K-Nearest-Neighbours, PAMR - Shrunken Centroids,
SOM - Self Organized Maps, and SVM - Support Vector
Machines. See GEPAS [3] for details in F-ratio, error estimation,
and classification methods. Dataset, normal or tumour data, and
class is specified in each plot.
(EPS)
Figure S5 Functional networks representing known
interaction between genes expressed in normal tissue
and selected in the models predictive of capsular
penetration. The figure represents the four most significant
networks selected by the IPA software for the Singh et al. dataset
[4]. Genes represented in the predictive models are represented by
blue shapes. Genes in the networks are arranged by cellular
localization (extracellular, membrane, cytoplasm and nucleus).
(TIFF)
Figure S6 Induction of pro-metastatic cytokines in
RWPE1 cells by Interleukin 1b. The transcriptional response
of normal prostate epithelial cells (RWPE1) was measured with
human Agilent microarrays 6 hours and 24 hours after addition of
100 ng/ml of recombinant human Interleukin 1b (eBioscience,
USA). The experiments were performed three times in different
days. Genes represented in Figure 4A were then tested for
differential expression using a t-test. Only the pro-metastatic
chemokines CCL20 (Panel B) and CX3CL1 (Panel C) were
differentially expressed (**, FDR,1%) at both time points. The
gene LOX was only transiently activated by Interleukin 1b six
hours post exposure (Panel D). Panel A shows the portion of the
network in Figure 4A where genes are differentially expressed in
RWPE1 in response to Interleukin 1b exposure. In this experiment
RWPE1 cells were grown in 0.4% gelatin coated plates, complete
KSFM media supplemented with L-Glutamine, p/s, BPE and
EGF.
(TIFF)
Figure S7 Expression of selected secreted factors and
receptors in Tomlins et al. dataset. Nor, Adj, BPH, PIN,
PCA-Low, PCA-High and Meta samples are described in main
paper.
(TIFF)
Figure S8 Comparison of the expression of selected
secreted factors and receptors in Tomlins et al. dataset.
Panels A-L represents the expression profile (y axis) of a selection
of the genes differentially expressed between all LCM cell
populations (shown as a heat map in figure 5 in main paper).
The different cell populations are arranged along the x axis. Red
close circles represent gene expression levels significantly different
(P,0.01) respect to adj cells whereas blue close circles inside red
circles represent gene expression levels significantly different
(p,0.05) respect to adj cells. Nor, Adj, BPH, PIN, PCA-Low,
PCA-High and Meta samples are described in main paper.
(TIFF)
Table S1 Datasets annotation. As stated, we used approx-
imately the 25% of the database (marked in bold). Overlaps were
estimated by Unigene annotation. Similar results are obtained
using entrez id or gene symbol as shown in columns. 50% Top
genes were estimated relaxing the filter range in both datasets to
25 and 50%.
(DOCX)
Table S2 Significant Networks identified by the Inge-
nuity Pathway Analysis (IPA) software associated to
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PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e16492models developed using the GA-MLHD procedure. The
table lists the networks identified from the Lapointe et al. [2]
dataset associated to models predictive of tumour capsular
penetration from the molecular profile of normal cells. HCG
Column highlights the network highest connected gene(s) or
complex. Genes in bold were part of the multivariate models used
as input for IPA analysis.
(DOCX)
Table S3 Selected secreted factors and receptors. Genes
obtained in IPA networks and present in Tomlins et al. dataset
were selected. P-Values were estimated using f-test comparing
Nor, Adj, BPH, PIN, PCA-Low, PCA-High and Meta samples as
shown in Figure 5 and Supplementary Figure S6. Some genes are
represented by different probes in the microarray platform used.
Only probes with p-Value ,0.001 were included in Figure 5.
(DOCX)
Table S4 Overlap of the top 50 selected genes in models
using larger datasets for Singh et al. dataset. Numbers in
upper triangular matrix correspond to the number of genes
overlapped. Underlined numbers in lower triangular matrix
correspond to the p-value testing the corresponding overlap
number using a hypergeometric test. All comparisons were
significant at the 0.05 level.
(DOCX)
Table S5 Overlap of the top 50 selected genes in models
using larger datasets for Lapointe et al. dataset. Numbers
in upper triangular matrix correspond to the number of genes
overlapped. Underlined numbers in lower triangular matrix
correspond to the p-value testing the corresponding overlap
number using a hypergeometric test. All comparisons were
significant at the 0.05 level.
(DOCX)
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